Methotrexate and Survival in Childhood Leukemia
Author Information
Author(s): A.D.J. Pearson, H.A. Amineddine, M. Yule, S. Mills, D.R. Long, A.W. Craft, J.M. Chessells
Primary Institution: Hospital for Sick Children, Great Ormond Street, London
Hypothesis
Does the concentration and dosage of methotrexate affect event-free survival in children with acute lymphoblastic leukemia?
Conclusion
Higher serum concentrations of methotrexate were not associated with improved event-free survival in children with acute lymphoblastic leukemia.
Supporting Evidence
- Higher serum concentration and area under the plasma concentration curve were not associated with improved event-free survival.
- Patients who tolerated only low doses of 6-mercaptopurine had a lower rate of leukemia relapse.
- Intramuscular methotrexate produced higher peak concentrations but did not improve survival.
Takeaway
This study looked at how methotrexate, a cancer drug, works in kids with leukemia. It found that just having more of the drug in their blood didn't help them do better.
Methodology
The study involved 127 children receiving methotrexate for leukemia, comparing oral and intramuscular administration and measuring drug concentrations and event-free survival.
Potential Biases
Potential bias due to variations in drug administration and patient compliance.
Limitations
The study did not account for patient and physician compliance in drug administration.
Participant Demographics
Children aged 0.86 to 13.62 years, median age 4.34 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website